Circassia Group Plc (CIR):企業の財務・戦略的SWOT分析

◆英語タイトル:Circassia Group Plc (CIR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH135228FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Circassia Group Plc (CIR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Circassia Group Plc (Circassia), formerly Circassia Pharmaceuticals plc develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used for asthma management. The company offers its products to asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.

Circassia Group Plc Key Recent Developments

Nov 13,2020: Circassia Group: Board appointment
Nov 10,2020: Circassia Group: Change of registered office
Sep 17,2020: Circassia Group : Interim results for the six months ended 30 June 2020
Jun 16,2020: Circassia Group : Preliminary results for the year ended 31 December 2019
May 01,2020: Circassia Pharmaceuticals: Change of name effective

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Circassia Group Plc – Key Facts
Circassia Group Plc – Key Employees
Circassia Group Plc – Key Employee Biographies
Circassia Group Plc – Major Products and Services
Circassia Group Plc – History
Circassia Group Plc – Company Statement
Circassia Group Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Circassia Group Plc – Business Description
Business Segment: COPD (US AZ collaboration)
Overview
Performance
Business Segment: LungFit PH
Overview
Performance
Business Segment: Niox Segment
Overview
Performance
Geographical Segment: Asia Pacific
Performance
Geographical Segment: EU
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
Circassia Group Plc – SWOT Analysis
SWOT Analysis – Overview
Circassia Group Plc – Strengths
Circassia Group Plc – Weaknesses
Circassia Group Plc – Opportunities
Circassia Group Plc – Threats
Circassia Group Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Circassia Group Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 13, 2020: Circassia Group: Board appointment
Nov 10, 2020: Circassia Group: Change of registered office
Sep 17, 2020: Circassia Group : Interim results for the six months ended 30 June 2020
Jun 16, 2020: Circassia Group : Preliminary results for the year ended 31 December 2019
May 01, 2020: Circassia Pharmaceuticals: Change of name effective
Feb 28, 2020: Circassia Pharmaceuticals: re Board appointment
Jan 09, 2020: Circassia announces business update
Dec 05, 2019: Circassia announces board changes
Sep 26, 2019: Circassia Pharmaceuticals: Interim results for the six months ended 30 June 2019
Aug 12, 2019: Circassia appoints Industry Veteran Jonathan Emms as Chief Operating Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Circassia Group Plc, Key Facts
Circassia Group Plc, Key Employees
Circassia Group Plc, Key Employee Biographies
Circassia Group Plc, Major Products and Services
Circassia Group Plc, History
Circassia Group Plc, Subsidiaries
Circassia Group Plc, Joint Venture
Circassia Group Plc, Key Competitors
Circassia Group Plc, Ratios based on current share price
Circassia Group Plc, Annual Ratios
Circassia Group Plc, Annual Ratios (Cont...1)
Circassia Group Plc, Interim Ratios
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Circassia Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Circassia Group Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Circassia Group Plc (CIR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • National OilWell Varco, Inc.:企業の戦略・SWOT・財務情報
    National OilWell Varco, Inc. - Strategy, SWOT and Corporate Finance Report Summary National OilWell Varco, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • C. Uyemura & Co., Ltd. (4966):企業の財務・戦略的SWOT分析
    C. Uyemura & Co., Ltd. (4966) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Biomay AG-製薬・医療分野:企業M&A・提携分析
    Summary Biomay AG (Biomay) discovers and develops disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. Its pipeline product portfolio comprises investigation candidates targeted against IgE mediated diseases, grass pollen allergy, ho …
  • Evolving Systems Inc (EVOL):企業の財務・戦略的SWOT分析
    Summary Evolving Systems Inc (Evolving Systems) is a technology company that provides development, delivering and supporting technologies and vendor independent software solutions. The company offers software solutions such as real-time lifecycle marketing, dynamic sim allocation, tertio service act …
  • Transocean Ltd.:企業の戦略・SWOT・財務情報
    Transocean Ltd. - Strategy, SWOT and Corporate Finance Report Summary Transocean Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Poxel SA (POXEL):企業の財務・戦略的SWOT分析
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • Ontario Power Generation Inc-エネルギー分野:企業M&A・提携分析
    Summary Ontario Power Generation Inc. (OPG) is an electricity generating company, fully owned by the Government of Ontario. It carries out the generation and sale of electricity in Ontario. The company generates electricity by utilizing various sources of energy including nuclear, hydroelectric, bio …
  • Nestle Pakistan Limited:企業の戦略・SWOT・財務情報
    Nestle Pakistan Limited - Strategy, SWOT and Corporate Finance Report Summary Nestle Pakistan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vascutek Ltd:製品パイプライン分析
    Summary Vascutek Ltd (Vascutek), a subsidiary of Terumo Corp is a medical equipment company that designs, manufactures and distributes vascular and cardiovascular products. The company provides products such as stent graft system, aortic root designs, polyester products and EPTFE products, among oth …
  • Landesbank Hessen Thueringen Girozentrale:企業の戦略・SWOT・財務情報
    Landesbank Hessen Thueringen Girozentrale - Strategy, SWOT and Corporate Finance Report Summary Landesbank Hessen Thueringen Girozentrale - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • LCH.Clearnet Group Limited:企業の戦略・SWOT・財務情報
    LCH.Clearnet Group Limited - Strategy, SWOT and Corporate Finance Report Summary LCH.Clearnet Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Sao Martinho SA (SMTO3):企業の財務・戦略的SWOT分析
    Sao Martinho SA (SMTO3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • HCA Healthcare Inc (HCA):企業の財務・戦略的SWOT分析
    HCA Healthcare Inc (HCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Skechers USA Inc (SKX):企業の財務・戦略的SWOT分析
    Skechers USA Inc (SKX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • CryoLife Inc (CRY):企業の財務・戦略的SWOT分析
    CryoLife Inc (CRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Genome British Columbia:医療機器:M&Aディール及び事業提携情報
    Summary Genome British Columbia (Genome BC) is a non-profit medical research organization that conducts genomics and proteomics research, and offers science and technology solutions. The organization provides prognostic, new diagnostic, and therapeutic tools for use in personalized medicine. It also …
  • Pint Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Pint Pharma GmbH (Pint Pharma), a subsidiary of Pint Pharma International SA, is a developer, manufacturer and marketer of originator drugs in rare disease, oncology and specialty conditions. The company offers its products in the form of tablets, injections, small compounds, drugs, implants …
  • Genticel SA (GTCL)-製薬・医療分野:企業M&A・提携分析
    Summary Genticel SA (Genticel), formerly BT Pharma, is a biopharmaceutical company that develops therapeutic vaccines for women infected by the human papillomavirus. The company provides pipeline products including ProCervix, a bivalent HPV therapeutic vaccine candidate and multivalent candidate vac …
  • Silence Therapeutics Plc (SLN)-製薬・医療分野:企業M&A・提携分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a research and development company that develops and delivers RNA interference therapeutics for the treatment of serious diseases. The company's pipeline products include Atu027 and Atu111. Its Atu027 is developed for …
  • Metropolitan Bank & Trust Company (MBT):企業の財務・戦略的SWOT分析
    Metropolitan Bank & Trust Company (MBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆